Founded in 2013 by CEO Hugues Bultot, Univercells brings biology, manufacturing, and technology together to provide clients with solutions to the rising costs of vaccine production. The company does so by developing platforms for the creation of local bioproduction facilities.
The company intends to use the grant to develop a vaccine manufacturing platform that will make vaccines more affordable and accessible in developing countries.
Univercells will form a consortium with Batavia Biosciences and Natrix Separations in order to execute the development of the platform. Taking advantage of Univercells’ process intensification and integration capabilities and technologies; Natrix’s innovative single-use chromatography membrane platform; and Batavia’s vaccine development and manufacturing capabilities, the goal of this collaboration is to create a micro-facility for inactivated polio vaccine (sIPV) that will produce 40 million doses of trivalent vaccine per year at a manufacturing cost of less than $0.15 per dose.
You can subscribe to Tech.eu’s newsletter here.
This story originally appeared on Tech.eu. Copyright 2017
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more